National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Dupilumab (Dupixent®) for severe atopic dermatitis in children 6 to 11 years old. HTA ID: 21035

Dupilumab is indicated for severe atopic dermatitis in children 6 to 11 years old who are candidates for systemic therapy.

 

NCPE Assessment Process Complete
Rapid review commissioned 30/08/2021
Rapid review completed 23/09/2021
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that dupilumab not be considered for reimbursement at the submitted price*.

 

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.